Moffitt Cancer Center Appoints Cathy Kerzner Interim CEO of M2Gen™

December 02, 2010

Tampa, Fla.Cathy Kerzner has been named interim chief executive officer of M2Gen, a wholly owned for-profit subsidiary of Moffitt Cancer Center. Kerzner previously held the title of Chief Commercial Officer of M2Gen™.

Kerzner is responsible for developing and implementing effective growth strategies, determining commercialization opportunities, and establishing and executing pharmaceutical company-funded clinical trials. She will cultivate new and more efficient means of collecting clinical data electronically, as well as direct and raise required capital at appropriate valuations.

Prior to joining M2Gen™, Kerzner served as senior vice president of commercial portfolio management at Wyeth Pharmaceuticals. She was responsible for strategic planning, portfolio management, global pricing and reimbursement, global forecasting and new business development. In this role, she was accountable for developing company strategy, optimizing commercial opportunities and overseeing the new products pipeline.

Kerzner previously was senior vice president and general manager of the Women’s Health Care Business Unit at Wyeth, with profit-and-loss responsibility for its global business. She also led its U.S. marketing, sales and headquarters commercial organizations. Prior to this post, she served in various roles with Wyeth for 14 years.

Kerzner also formerly served as vice president of commercial strategy for Cardinal Health in Wayne, N.J., and was the co-founder of EKR Therapeutics, Inc., a New Jersey-based specialty pharmaceutical company focused on the acquisition and commercialization of acute care hospital products.

Kerzner holds a Bachelor of Commerce from the University of Toronto and an M.B.A. from York University in Toronto. She is a corporate past-president, adviser and mentor to the Healthcare Businesswomen’s Association.

About M2Gen™

M2Gen™ is Moffitt Cancer Center’s wholly owned, for-profit subsidiary focused on advancing personalized medicine by using high quality tissue, clinical data and molecular technology to advance targeted cancer treatments. M2Gen, along with Moffitt and 18 hospitals in a Consortium Network, has created the world’s largest cancer-focused biorepository linked to clinical and molecular data. Since 2006, M2Gen has partnered with Merck & Co., Inc., to fulfill its vision for transforming cancer treatment and improving patient outcomes.

About Moffitt Cancer Center

Located in Tampa, Florida, Moffitt Cancer Center  is an NCI Comprehensive Cancer Center - a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.